Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,559,269

« Back to Dashboard

Summary for Patent: 5,559,269

Title: 3,3-diphenylpropylamines, their use and preparation
Abstract:The invention relates to 3,3-diphenylpropylamines of formula (I), wherein R.sup.1 signifies hydrogen or methyl, R.sup.2 and R.sup.3 independently signify hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula (II), wherein R.sup.4 and R.sup.5 signify non-aromatic hydrocarbyl groups, which may be the same or different and which together contain at least three carbon atoms, and wherein R.sup.4 and R.sup.5 may form a ring together with the amine nitrogen, their salts with physiologically acceptable acids and, when the compounds can be in the form of optical isomers, the racemic mixture and the individual enantiomers. The invention also relates to methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs ##STR1##
Inventor(s): Johansson; Rolf A. (Huddinge, SE), Moses; Pinchas (Satsj o-Boo, SE), Nilvebrant; Lisbeth (Bromma, SE), Sparf; Bengt .ANG.. (Tr.ang.ngsund, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:08/432,113
Patent Claim Types:
see list of patent claims
Compound; Composition; Process; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,559,269

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9203318Nov 06, 1992

International Patent Family for Patent: 5,559,269

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland952179► subscribe
Canada2148827► subscribe
Germany69317898► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.